

Rhythm Biosciences Limited
Appendix 4E
Preliminary final report

1. Company details

Name of entity:	Rhythm Biosciences Limited
ABN:	59 619 459 335
Reporting period:	For the year ended 30 June 2023
Previous period:	For the year ended 30 June 2022

2. Results for announcement to the market

		2023	2022
		\$	\$
Other income from ordinary activities	Up 36%	3,324,112	2,452,371
Loss from ordinary activities after tax attributable to the owners of Rhythm Biosciences Limited	Down 7% to	(8,217,557)	(8,793,521)
Comprehensive loss for the year attributable to the owners of Rhythm Biosciences Limited	Down 7% to	(8,217,557)	(8,793,521)

Dividends

There were no dividends paid, recommended or declared during the financial year.

Comments

The loss for the consolidated entity after providing for income tax was \$8,217,557. Comments on activities during the year are included in the Executive Chairman's Report in the Annual Report attached.

3. Net tangible assets

	Reporting period	Previous period
	Cents	Cents
Net tangible assets per ordinary security	<u>2.46</u>	<u>3.16</u>

4. Control gained over entities

In the United Kingdom, Rhythm Biosciences UK Limited, was incorporated on 23 June 2023 as a 100% owned subsidiary.

5. Loss of control over entities

Not applicable.

6. Details of associates and joint venture entities

Not applicable.

Rhythm Biosciences Limited
Appendix 4E
Preliminary final report

7. Audit qualification or review

Details of audit/review dispute or qualification (if any):

The financial statements have been audited and an unqualified opinion has been issued.

8. Attachments

Details of attachments (if any):

The Annual Report of Rhythm Biosciences Limited for the year ended 30 June 2023 is attached.

9. Signed



Otto Buttula
Executive Chairman

Date: 31 August 2023